Home › Research › Treatments
Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease
Hendriks J, Antoniou M, Babic I. Zenodo (CERN European Organization for Nuclear Research), 2026-04-23
Topic: Amyloid, tau and blood-test diagnosis
Lecanemab reduced clinical decline by roughly 27% over placebo, with ARIA-E in 12.6% of treated patients;donanemab slowed decline by about 35%, with ARIA-E near 24%. Aducanumab trials gave discordant results. ARIA risk risesseveral-fold in APOE4 homozygotes, and rare fatal hemorrhages have followed anticoagulation or thrombolysis. Anti-amyloid antibodies offer modest, genuine benefit, but safe use depends on genotype-informed eligibilityscreening and structured serial MRI monitoring.
Key findings
- Lecanemab reduced clinical decline by roughly 27% over placebo, with ARIA-E in 12.6% of treated patients;donanemab slowed decline by about 35%, with ARIA-E near 24%.
- Aducanumab trials gave discordant results.
- ARIA risk risesseveral-fold in APOE4 homozygotes, and rare fatal hemorrhages have followed anticoagulation or thrombolysis.
- Anti-amyloid antibodies offer modest, genuine benefit, but safe use depends on genotype-informed eligibilityscreening and structured serial MRI monitoring.
Why it matters
Lecanemab and donanemab give modest but genuine slowing of decline in early Alzheimer disease, while aducanumab trials gave discordant results. Safe use depends on genotype-informed eligibility screening and structured serial MRI monitoring because of ARIA risk, which rises several-fold in APOE4 homozygotes.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designnarrative review
- Effect size12.6%
- Evidence strengthHigh
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 32 of the 64 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 32 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 32 of the 64 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Hendriks, J., Antoniou, M., & Babic, I. (2026). Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.22310607
Vancouver
Hendriks J, Antoniou M, Babic I. Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.22310607.
BibTeX
@article{hendriks2026-95d6b60f,
author = {Hendriks, J. and Antoniou, M. and Babic, I.},
title = {{Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease}},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.22310607},
url = {https://doi.org/10.5281/zenodo.22310607}
}
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.